Details of the Drug Combination

General Information of Drug Combination (ID: DC8VJSG)

Drug Combination Name
PF-04958242 PF-04958242
Indication
Disease Entry Status REF
Schizophrenia Phase 1 [1]
Component Drugs PF-04958242   DMRAFBK PF-04958242   DMRAFBK
N.A. N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PF-04958242
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 2 [2]
PF-04958242 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Activator [2]
------------------------------------------------------------------------------------
Indication(s) of PF-04958242
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 2 [2]
PF-04958242 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Activator [2]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Schizophrenia DCIPJIR N. A. Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01511510) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 ClinicalTrials.gov (NCT01518894) A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia